Marc Watson

Marc Watson has worked in the field of research and development for the past 17 years. In 2003, they began their career as a Research Scientist (PhD placement) at Biogen Idec. Following this, they worked as a Postdoctoral Researcher at the University of Manchester, where they conducted studies into the molecular mechanisms underlying integrin mediated synaptic and intracellular signalling in neurons. In 2005, they moved to the MRC Laboratory for Molecular Cell Biology (LMCB) at UCL, where they were a Postdoctoral Career Development Fellow. During this time, they investigated the effects of neurotrophin dependent nitric oxide production on neuronal gene regulation, using primary cell cultures of mammalian neurones. This work lead to a publication in Nature. In 2008, they became a Scientist I at MedImmune. In 2014, they were promoted to Senior Scientist at Takeda. Marc then moved to Cerevance in 2016, where they were a Senior Scientist, Cellular Neurobiology. In 2017, they were promoted to Principal Scientist at Mission Therapeutics. Most recently, they have been the Research Director at Transine Therapeutics since 2020.

Marc Watson completed their education with a Doctor of Philosophy (PhD) in Neuroscience from The University of Manchester in 2004. Prior to that, they earned a Master's degree in MRes (Biological Sciences) from The University of Manchester in 2001. Watson began their education in 1996, graduating with a Bachelor of Science (BSc) in Genetics from The University of Edinburgh in 2000.